The Loom

A quarterly newsletter from Weave

Vol 03
Oct 2025

Pg 1 Series A
Pg 2 New Releases
Pg 3 Partnerships
Pg 4 Team & Events

$20M Series A to Power What's Next

We're pleased to share that we've raised $20 million in Series A funding to accelerate development of our AI-native regulatory platform, designed to help life sciences teams bring therapies to patients faster and with greater confidence. The round was led by USVP, with participation from Innovation Endeavors, Magnetic Ventures, Character, TMV, and Serrado Capital, bringing our total capital raised to $36 million.

Regulatory work is fundamental to the success of every therapy, yet it continues to be one of the most complex and resource-intensive areas of drug development. We founded Weave on the belief that AI can work hand-in-hand with regulatory experts to improve the quality, clarity, and scalability of the process—not just accelerate it.

With this investment, we're expanding the Weave Platform to support the full regulatory lifecycle, including IND, NDA, and BLA submissions, health authority responses, and post-market updates. The funding will also support our growth into additional global regulatory regions such as Europe, Japan, and Latin America, enabling customers to manage submissions across markets within a single platform.

By embedding AI into every stage of the regulatory process—from organizing source data to drafting, verification, and lifecycle management—we're helping teams improve submission quality, reduce regulatory risk, and gain greater visibility into their development programs.

View full announcement

A Note From Brandon Rice, Our CEO

Having just returned from RAPS Convergence in Pittsburgh and Fierce Biotech in Boston, two things were impossible to miss:

AI is cool now
Everyone has AI

The potential of the latest AI technologies to produce tremendous positive impact is now widely believed and accepted. But as a result, every booth is emblazoned with "AI" and it is becoming increasingly difficult to navigate the maze of offerings and promises. Personally, I am of the belief that we're entering the "proof" phase of LLMs/AI, defined by: happiness for users and ROI for organizations. Thankfully, these are two of our highest values at Weave, so I'm optimistic on our chances.

In general we prefer to demonstrate those values by showing over telling, so in this newsletter we'll share our proof, including our recent financing, our partnership with Parexel, and more. Each of these advances us toward our singular goal: to help drug companies bring drugs to market as rapidly, efficiently, and confidently as possible.

We collaborate with our customers every day on this journey, and we've still got a long way to go. If you've already joined us, thank you! If you haven't, we'd love to have you.

Q3 Release Highlights: Smarter, Faster Regulatory Workflows

This quarter, we focused on one goal: helping teams move through regulatory milestones with greater speed, accuracy, and confidence, without adding more work to their plates. The latest release introduces AI capabilities that automatically verify your data and keep your documents up to date as new information becomes available, so you can stay inspection-ready at every stage of development.

Automatic Data Verification: Built-In Accuracy

Manual data checking has long been one of the most time-consuming parts of regulatory writing. Weave now reviews each sentence automatically against your source files, flagging potential discrepancies with links back to the original data.

Teams gain instant visibility into accuracy, reducing manual review cycles and increasing confidence that every statement is supported by the right evidence.

The benefits:

- Verified statements can be trusted without additional manual review
- Potential issues are surfaced immediately for correction
- Teams improve submission quality while reducing review time

AutoUpdate: Stay Current as Data Changes

Keeping documents current is critical. AutoUpdate monitors your source files and detects when new or updated data may impact a draft. It highlights the exact sections that require revision and allows teams to review and apply changes directly.

Each document stays aligned with the most current information, enhancing quality and consistency across programs and reducing the work needed to remain up to date.

The benefits:

- Updated data is found automatically, eliminating manual tracking
- Content stays accurate and aligned as programs progress
- Teams reduce update cycles from days to hours

Read full release notes

Veeva Vault Integration

Weave now integrates directly with Veeva Vault, enabling regulatory teams to work in one connected system where files flow automatically and accuracy is always maintained.

Source documents are continuously synced from Veeva into the Weave Platform and organized by program, so teams can start drafting immediately with the most current data. When ready, documents can be exported back to Veeva with the correct classifications, eliminating manual steps and ensuring system alignment.

What this means for teams:

- Eliminates the need to manage documents in multiple systems
- Ensures files stay current automatically without manual syncing
- Reduces the risk of versioning errors across teams and programs
- Supports greater consistency and accuracy throughout the regulatory lifecycle

Watch this in action

Upcoming Releases

We're getting ready to introduce **Weave's HAQ Manager**, a new product designed to help teams move faster through the next phase of the regulatory journey. It will bring structure and speed to every Health Authority Question, turning last-minute requests into organized, confident responses.

Register for our November 14 webinar for a first look.

You can find previous release notes on our **website resources** page.



Partner Spotlight: Weave and Parexel Advance Regulatory Innovation

We're excited to share that we've partnered with Parexel, one of the world's leading clinical research organizations (CROs), to accelerate how new therapies reach patients.

This collaboration combines Parexel's deep regulatory and clinical expertise with the AI-native Weave Platform, creating a faster, smarter path from discovery to approval.

> AI tools are only as strong as the people behind them. Through this partnership, Weave will tap into Parexel's deep regulatory expertise to refine and expand our solutions across the drug development industry."
>
> — Lindsay Mateo, CCO, Weave

As CRO design partner, Parexel is helping us refine and expand the Weave Platform across every stage of the regulatory lifecycle. Parexel will also maintain a period of exclusivity as the only CRO using the AI templates developed in the partnership with our team, reflecting their leadership in innovation for sponsors and commitment to advancing regulatory science through responsible AI adoption.

Together, we're tackling one of the most urgent challenges in drug development: early regulatory authoring and submission preparation. By combining Parexel's human-in-the-lead approach with Weave's intelligent automation, we're helping teams deliver high-quality submissions faster, with greater confidence and control.

Parexel has already used the Weave Platform to prepare Investigational New Drug (IND) applications 50% faster than traditional authoring timelines. This demonstrates the real-world impact of AI-driven efficiency paired with expert regulatory insight.

Learn more about Parexel's leadership in clinical research and regulatory innovation at **parexel.com**

Weave and Takeda Study: Human+AI Reshaping Regulatory Writing

In collaboration with Takeda, our newly published study, "Human–AI Collaboration Increases Efficiency in Regulatory Writing" (arXiv:2509.09738), explores how the Weave Platform drives significant gains in both speed and accuracy during regulatory drafting.

In the study, two experienced regulatory writers used the platform's AI-driven authoring environment to complete tasks that typically require over 100 hours in just 2.6 to 3.7 hours, approximately 97% reduction in first-draft time.

The AI-generated drafts were assessed against traditional human-written documents, earning quality scores of 89.5% and 66.7%, with no critical regulatory errors observed in either trial. The research covered some of the most complex IND sections, including pharmacology, pharmacokinetics, and toxicology, using a quality scoring framework that evaluated correctness, completeness, conciseness, clarity, and emphasis.

These findings reinforce our core belief: AI accelerates, but human expertise remains essential. While Weave's platform handles the data-driven drafting, human authors provide the context and judgment required to meet the highest regulatory standards. Together, they create a process that's not just faster but stronger.

A big thank you to Takeda for their collaboration and shared vision in advancing the human–AI partnership in regulatory writing.

Read full study or **view summary**

Come Build with Us

Generative AI is reshaping drug development, and Weave is helping teams focus on what matters most, getting therapies to patients.

As more companies turn to Weave to power their regulatory workflows, our team is growing across product, engineering, AI research, and go-to-market roles. Join us in shaping the future of this industry.

Current openings include:

- Go-to-Market – Account Executives (Biotech & Enterprise), Principal Customer Success Manager, Product Marketing Manager, Vice President of Sales, Sales Development Representative
- Engineering – AI Engineering Team Lead, Frontend Engineering Team Lead, Senior/Staff Backend Engineer, Senior/Staff Frontend Engineer
- Product – Senior Product Manager
- Research & Strategy – AI Research Scientist

If you or someone you know is passionate about improving how life-saving medicines reach patients faster, we'd love to meet.

Explore careers page

New Weavers

Our newest Weavers bring curiosity, creativity, and deep experience to our shared mission of transforming how teams work.

- Joseph Durias, Director, Customer Success
- David Finkelson, Manager, Business Development
- Robin Horca, Office Manager/Executive Assistant
- Mariya Kolesnikova, AI Implementation Specialist
- Sarah Miller, Recruiter
- Ben Wolin, Staff Backend Engineer

See Us in Action

Our team's out and about at upcoming industry events. Come say hello and see what we're working on.

- American Medical Writers Association | Nov 5-8 | Phoenix
- HAQ Manager Product Webinar | Nov 14 | Zoom
- AI Drug Development & Discovery Summit | Nov 18-20 | Boston
- Happy Hour & Lunch and Learn | Dec 4-5 | La Jolla

See where we will be

Weave is an AI-native platform built to help life sciences teams bring therapies to patients faster and with greater confidence.

By combining human expertise with intelligent automation, Weave streamlines regulatory workflows—simplifying the creation, review, and management of regulatory content across the development lifecycle.

weave

info@weave.bio